Losartan Potassium
Product Images NDC 53002-1624

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53002-1624). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure01 (Figure01)

Figure01 (Figure01)
The text contains data related to a study that compares the effectiveness of Atenolol and Losartan Potassium in reducing the risk of a primary endpoint in patients. The text shows a graph displaying the study month against the percentage of patients with the primary endpoint. Additionally, the text mentions an adjusted risk reduction of 13% with a p-value of 0.021.*
FDA Label Image

Figure02 (Figure02)

Figure02 (Figure02)
The text provides information on a comparison between Atenolol and Losartan potassium in terms of the percentage of patients who suffered from fatal/non-fatal strokes. The adjusted risk reduction percentage and p-value are also mentioned. The study tracked patients for a period of 66 months.*
FDA Label Image

Figure03 (Figure03)

Figure03 (Figure03)
The text describes the results of a study comparing the effectiveness of Losartan K and atenolol for preventing fatal/near-fatal strokes. The study involved participants of different genders, races, and medical histories, and the results showed a slight advantage for Losartan K. The study was adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
FDA Label Image

Figure04 (Figure04)

Figure04 (Figure04)
This is a summary of a clinical trial that compared the effectiveness of the drug Losartan Potassium (20r) to a placebo. The trial measured the risk reduction percentage, which was found to be 16.1%. The trial also reported a statistical significance level of p=0.022. The number 401 is likely a reference to the total number of patients included in the trial. The meaning of "asassss" is not clear and may be a result of error. The phrase "% patients with event" suggests that the trial measured the occurrence of some type of event, but without further context it is not clear what that event was.*
FDA Label Image

Label Image (Lbl530021624)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.